

Janis M Taube

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6354548/publications.pdf>

Version: 2024-02-01

147
papers

55,405
citations

15466

65
h-index

10424

139
g-index

155
all docs

155
docs citations

155
times ranked

51724
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	13.9	10,727
2	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
3	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
4	Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. <i>Journal of Clinical Oncology</i> , 2010, 28, 3167-3175.	0.8	2,667
5	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	12.8	2,133
6	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5064-5074.	3.2	2,050
7	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	0.8	2,015
8	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. <i>Science Translational Medicine</i> , 2012, 4, 127ra37.	5.8	1,837
9	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	13.9	1,668
10	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	13.9	1,495
11	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. <i>Cancer Discovery</i> , 2015, 5, 43-51.	7.7	1,180
12	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
13	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1973-1985.	13.9	871
14	Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 1733-1741.	0.4	678
15	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1051.	3.4	658
16	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2016, 76, 227-238.	0.4	595
17	Neoadjuvant checkpoint blockade for cancer immunotherapy. <i>Science</i> , 2020, 367, .	6.0	553
18	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. <i>Clinical Cancer Research</i> , 2013, 19, 462-468.	3.2	485

#	ARTICLE	IF	CITATIONS
19	PD-1/PD-L1 inhibitors. <i>Current Opinion in Pharmacology</i> , 2015, 23, 32-38.	1.7	483
20	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1195.	3.4	431
21	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. <i>American Journal of Pathology</i> , 2011, 179, 1608-1615.	1.9	423
22	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	1.6	400
23	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 580-588.	3.9	388
24	Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. <i>Gut</i> , 2017, 66, 794-801.	6.1	377
25	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. <i>Clinical Cancer Research</i> , 2017, 23, 124-136.	3.2	345
26	Alterations of immune response of non-small cell lung cancer with Azacytidine. <i>Oncotarget</i> , 2013, 4, 2067-2079.	0.8	336
27	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. <i>Cancer Immunology Research</i> , 2013, 1, 54-63.	1.6	333
28	Detection of Transcriptionally Active High-risk HPV in Patients With Head and Neck Squamous Cell Carcinoma as Visualized by a Novel E6/E7 mRNA In Situ Hybridization Method. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1874-1882.	2.1	308
29	Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). <i>Annals of Oncology</i> , 2018, 29, 1853-1860.	0.6	304
30	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. <i>Human Pathology</i> , 2016, 47, 52-63.	1.1	284
31	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
32	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	0.8	274
33	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	0.8	259
34	Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. <i>New England Journal of Medicine</i> , 2016, 374, 896-898.	13.9	244
35	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.	13.7	234
36	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.4	226

#	ARTICLE	IF	CITATIONS
37	Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive <i>p53</i> Gene Mutations in Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2008, 14, 366-369.	3.2	213
38	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202.	0.8	209
39	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. <i>Clinical Cancer Research</i> , 2015, 21, 3969-3976.	3.2	205
40	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. <i>Laboratory Investigation</i> , 2017, 97, 1063-1071.	1.7	156
41	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
42	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2476-2487.	0.8	152
43	B7-H5 costimulates human T cells via CD28H. <i>Nature Communications</i> , 2013, 4, 2043.	5.8	148
44	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7769-E7777.	3.3	145
45	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
46	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. <i>OncImmunity</i> , 2016, 5, e1134412.	2.1	135
47	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2016, 4, 726-733.	1.6	133
48	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133
49	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
50	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 7333-7339.	3.2	128
51	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	3.2	126
52	Interleukin-36 β -producing macrophages drive IL-17-mediated fibrosis. <i>Science Immunology</i> , 2019, 4, .	5.6	123
53	Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma. <i>Urology</i> , 2015, 85, 703.e1-703.e6.	0.5	122
54	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. <i>Clinical Cancer Research</i> , 2017, 23, 4938-4944.	3.2	120

#	ARTICLE	IF	CITATIONS
55	The immune microenvironment of breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2016, 29, 249-258.	2.9	119
56	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. , 2017, 5, 23.		118
57	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. <i>Science</i> , 2021, 372, .	6.0	114
58	Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes. <i>Nature Genetics</i> , 2015, 47, 933-938.	9.4	111
59	PEG hydrogel degradation and the role of the surrounding tissue environment. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2015, 9, 315-318.	1.3	108
60	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. <i>Cancer Immunology Research</i> , 2019, 7, 257-268.	1.6	108
61	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
62	Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. <i>International Journal of Cancer</i> , 2018, 143, 3201-3208.	2.3	101
63	Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3016-3016.	0.8	101
64	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 545-551.	3.2	100
65	PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq 1, 1 0.784314 rgBT 1.0 90	1.0	90
66	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.	3.2	90
67	Photoactivated Composite Biomaterial for Soft Tissue Restoration in Rodents and in Humans. <i>Science Translational Medicine</i> , 2011, 3, 93ra67.	5.8	88
68	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. , 2021, 9, e002568.		87
69	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. <i>Journal of Translational Medicine</i> , 2015, 13, 214.	1.8	84
70	Merkel Cell Carcinoma: Update and Review. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2011, 30, 48-56.	1.6	82
71	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	3.2	67
72	Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions. <i>American Journal of Surgical Pathology</i> , 2017, 41, 62-66.	2.1	66

#	ARTICLE	IF	CITATIONS
73	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 974.	3.4	65
74	Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 717-726.	0.6	63
75	Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. <i>OncImmunology</i> , 2014, 3, e963413.	2.1	62
76	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. <i>Clinical Cancer Research</i> , 2016, 22, 1161-1172.	3.2	57
77	Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1088-1095.	0.9	56
78	PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. <i>Journal of Neuro-Oncology</i> , 2015, 121, 251-259.	1.4	56
79	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1381-1389.	2.1	54
80	A Novel Role for CD36 in VLDL-Enhanced Platelet Activation. <i>Diabetes</i> , 2003, 52, 1248-1255.	0.3	52
81	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 5250-5259.	3.2	46
82	Combined Use of PCR-Based TCRG and TCRB Clonality Tests on Paraffin-Embedded Skin Tissue in the Differential Diagnosis of Mycosis Fungoides and Inflammatory Dermatoses. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 320-327.	1.2	45
83	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. <i>Cancer Immunology Research</i> , 2015, 3, 110-115.	1.6	45
84	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. <i>Cell Reports Medicine</i> , 2020, 1, 100139.	3.3	45
85	PD-L1 expression in medulloblastoma: an evaluation by subgroup. <i>Oncotarget</i> , 2018, 9, 19177-19191.	0.8	45
86	A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms. <i>American Journal of Clinical Pathology</i> , 2013, 139, 151-159.	0.4	44
87	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. , 2021, 9, e002197.		44
88	Benign Nodal Nevi Frequently Harbor the Activating V600E BRAF Mutation. <i>American Journal of Surgical Pathology</i> , 2009, 33, 568-571.	2.1	40
89	PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 938-943.	0.7	37
90	Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. <i>Journal of Cutaneous Pathology</i> , 2011, 38, no-no.	0.7	37

#	ARTICLE	IF	CITATIONS
91	Impact of Elastic Staining on the Staging of Peripheral Lung Cancers. American Journal of Surgical Pathology, 2007, 31, 953-956.	2.1	36
92	Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. Blood Advances, 2017, 1, 1324-1334.	2.5	36
93	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Modern Pathology, 2017, 30, 1551-1560.	2.9	35
94	Mitochondrial Mutations Are a Late Event in the Progression of Head and Neck Squamous Cell Cancer. Clinical Cancer Research, 2007, 13, 4331-4335.	3.2	34
95	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	157.7	33
96	HHV-8-positive and EBV-positive Intravascular Lymphoma. American Journal of Surgical Pathology, 2014, 38, 426-432.	2.1	32
97	Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. Frontiers in Oncology, 2018, 8, 649.	1.3	30
98	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. European Urology Oncology, 2022, 5, 113-117.	2.6	30
99	Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. Journal of Visualized Experiments, 2013, , .	0.2	28
100	Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations. Journal of Cutaneous Pathology, 2015, 42, 807-814.	0.7	26
101	Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. OncoImmunology, 2015, 4, e1029704.	2.1	26
102	Characterization of Human Mesenchymal Stem Cell-Engineered Cartilage: Analysis of Its Ultrastructure, Cell Density and Chondrocyte Phenotype Compared to Native Adult and Fetal Cartilage. Cells Tissues Organs, 2010, 191, 12-20.	1.3	25
103	To Control Site-Specific Skin Gene Expression, Autocrine Mimics Paracrine Canonical Wnt Signaling and Is Activated Ectopically in Skin Disease. American Journal of Pathology, 2016, 186, 1140-1150.	1.9	25
104	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine, 2017, 15, 223.	1.8	25
105	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research, 2019, 21, 72.	2.2	24
106	Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Cancer Immunology, Immunotherapy, 2021, 70, 1227-1237.	2.0	23
107	Emerging Immunologic Biomarkers: Setting the (TNM-Immune) Stage. Clinical Cancer Research, 2014, 20, 2023-2025.	3.2	22
108	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research, 2019, 7, 805-812.	1.6	22

#	ARTICLE	IF	CITATIONS
109	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. <i>Patterns</i> , 2021, 2, 100372.	3.1	22
110	Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. <i>World Neurosurgery</i> , 2020, 135, e187-e193.	0.7	19
111	Increased Expression of <i>PD-1</i> and <i>PD-L1</i> in Patients With Laryngotracheal Stenosis. <i>Laryngoscope</i> , 2021, 131, 967-974.	1.1	18
112	Pleuropulmonary Blastoma: Cytogenetic and Spectral Karyotype Analysis. <i>Pediatric and Developmental Pathology</i> , 2006, 9, 453-461.	0.5	16
113	Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 928-935.	0.7	16
114	PD-L1 expression in inflammatory myofibroblastic tumors. <i>Modern Pathology</i> , 2018, 31, 1155-1163.	2.9	15
115	Langerhans cell density and high-grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 565-570.	0.7	14
116	ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry. <i>Journal of Thoracic Oncology</i> , 2016, 11, S249.	0.5	11
117	Myofibroma, Myopericytoma, Myoepithelioma, and Myofibroblastoma of Skin and Soft Tissue. <i>Surgical Pathology Clinics</i> , 2011, 4, 745-759.	0.7	10
118	Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. <i>Melanoma Research</i> , 2017, 27, 85-96.	0.6	10
119	Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. <i>Prostate</i> , 2022, 82, 706-722.	1.2	10
120	Differentiated (Simplex) Vulvar Intraepithelial Neoplasia: A Case Report and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2011, 33, e27-e30.	0.3	8
121	Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. <i>Cancer Immunology Research</i> , 2021, 9, 1262-1269.	1.6	8
122	Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based pap preparation. <i>Diagnostic Cytopathology</i> , 2010, 38, 555-563.	0.5	7
123	Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance. , 2021, 9, e002642.		7
124	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA2509-CRA2509.	0.8	7
125	PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors. <i>Cureus</i> , 2019, 11, e6352.	0.2	7
126	Quantitative Assessment of the Immune Microenvironment in Patients With Iatrogenic Laryngotracheal Stenosis. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 1257-1264.	1.1	6

#	ARTICLE	IF	CITATIONS
127	Dermal and Subcutaneous Plexiform Soft Tissue Neoplasms. <i>Surgical Pathology Clinics</i> , 2011, 4, 819-842.	0.7	5
128	Plaque-like syringoma with involvement of deep reticular dermis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e206-e207.	0.6	5
129	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019). <i>TJ ETQq1.1 0.784314 rgBT</i>	1.8	5
130	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration "Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 394-401.	3.2	5
131	Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD therapy resemble acute graft versus host disease more than lichen planus. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 701-708.	0.7	4
132	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
133	Poliosis Circumscripta: A Mark of Melanoma. <i>American Journal of Medicine</i> , 2019, 132, 1417-1418.	0.6	3
134	Abstract 6584: The 'AstroPath' platform for spatially resolved, single cell analysis of the tumor microenvironment (TME) using multispectral immunofluorescence (mIF). , 2020, , .		3
135	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA2509-CRA2509.	0.8	3
136	Data-Rich Spatial Profiling of Cancer Tissue: Astronomy Informs Pathology. <i>Clinical Cancer Research</i> , 2022, 28, 3417-3424.	3.2	3
137	Haemophilus influenzae serotype f purulent pericarditis: a cause of death in a child with Down syndrome. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 87-89.	0.8	2
138	Follicular Mucinosis in a Male Adolescent with a History of Acute Myelogenous Leukemia and Graft-versus-Host Disease. <i>Pediatric Dermatology</i> , 2016, 33, e34-5.	0.5	2
139	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
140	Multifocal ischemic necroses of varying age (MINOVA): A distinctive form of atherosclerotic heart disease. <i>Pathology Research and Practice</i> , 2008, 204, 113-120.	1.0	1
141	Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies"Reply. <i>JAMA Oncology</i> , 2020, 6, 299.	3.4	1
142	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd). <i>TJ ETQq0 0.0 rgBT /Overlock 1</i>	1.8	1
143	Adaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8+ cell count.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4031-4031.	0.8	1
144	PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 300-300.	0.8	1

#	ARTICLE	IF	CITATIONS
145	PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers.. Journal of Clinical Oncology, 2012, 30, 5506-5506.	0.8	1
146	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	1.6	1
147	Safety and immunologic correlates of allogeneic melanoma GVAX (MelGVAX), a genetically engineered whole-cell melanoma vaccine.. Journal of Clinical Oncology, 2014, 32, e20001-e20001.	0.8	0